Phase 3 Alzheimer's Disease Trial, Recruiting NCT07115238 Sponsor: Sinotau Pharmaceutical Group Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07115238
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 50 years or older, of any gender
  • People who are able to undergo both PET scans and MRI scans
  • People who are willing to use contraception during the study and for 6 months after it ends
  • People who have provided written consent before any study assessments begin

For people with no memory or thinking problems, the following additional criteria apply:

  • A score of 0 on a standard memory and thinking assessment called the CDR
  • A score of 28 or higher on another standard thinking test called the MMSE
  • A brain scan showing no signs of a certain protein buildup (called amyloid) associated with Alzheimer's disease

For people with mild cognitive impairment (early memory or thinking difficulties):

  • A diagnosis of mild cognitive impairment that meets specific international medical guidelines from 2011
  • A brain scan showing signs of the amyloid protein buildup

For people with Alzheimer's disease:

  • A diagnosis that meets specific international medical guidelines from 2014
  • A brain scan showing signs of the amyloid protein buildup

Who may not be able to join:

  • People diagnosed with certain other types of dementia or related brain conditions, such as Lewy body dementia or frontotemporal dementia
  • People currently experiencing significant mental health symptoms that would prevent them from completing the scans
  • People whose MRI has shown significant structural brain abnormalities, such as a large stroke or a growth in the brain
  • People who experience severe anxiety in enclosed spaces (claustrophobia)
  • People with a history of alcohol or drug misuse or dependence
  • People who have a known allergy to the study drug or any of its ingredients
  • People who are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jiong Shi, Doctor, The First Affiliated Hospital of University of Science and Technology of China

Phone: 15512191857

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sinotau Pharmaceutical Group
Registry
ClinicalTrials.gov
Start date
20 November 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluate the effectiveness of visual reading of XTR006 PET imaging in detecting tau NFTs (neurofibrillary tangles)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov